Latest Protease inhibitor Stories
CAPE TOWN, South Africa, July 20 /PRNewswire/ -- New data became available today at the 5(th) International AIDS Society Conference from ARTEN (Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine [Truvada(R)] versus Nevirapine).
CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc.
KENILWORTH, N.J., July 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only.
BRISBANE, Calif., June 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Goldman Sachs 30th Annual Global Healthcare Conference in New York on June 9, 2009 at 2:35 p.m. ET.
Promising Anti-cancer Activity Observed in Relapsed Patients ORLANDO, Fla., and SOUTH SAN FRANCISCO, Calif. , May 30 /PRNewswire/ -- Proteolix, Inc.
- Results inform selection of doses, regimens to be explored in Phase 2b study - -- Phase 2b program anticipated to begin in summer 2009 -- COPENHAGEN, April 24 /PRNewswire-FirstCall/ -- InterMune, Inc.
CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc.
- Non-responder and Null Responder HCV patients - - Twice-Daily Dosing and Higher Doses of ITMN-191 (R7227) - BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc.
BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release first quarter 2009 financial results on Thursday, April 30, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m.
-- Conference Call and Webcast Scheduled -- BRISBANE, Calif., April 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that InterMune and Pharmasset, Inc.
- A poem in which the author retracts something said in an earlier poem.